Skip to content
POM-VPS Prescription Required

Diclacare 2.5 mg/ml Oral Suspension for Lambs and Calves

Active ingredient: Diclazuril

Form

Liquid

Species

Cattle Sheep

Manufacturer

Laboratorios Karizoo S.A

VMD MA No.

31223/3002

What it's used for

In calves: Prevention of clinical signs of coccidiosis caused by Eimeria bovis and Eimeria zuernii.

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Diclazuril

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Diclacare 2.5 mg/ml Oral Suspension for Lambs and Calves — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

In calves:
Prevention of clinical signs of coccidiosis caused by Eimeria bovis and Eimeria zuernii.
In lambs and calves:
1 mg diclazuril per kg body weight (1 ml of the oral suspension per 2.5 kg body weight),
as a single oral administration.
Shake well before use.
The use of suitably calibrated measuring equipment is recommended.
To ensure a correct dosage, body weight should be determined as accurately as possible.
If animals are to be treated collectively rather than individually, they should be grouped
according to their bodyweight and dosed accordingly, in order to avoid under- or
overdosing.
The oral suspension should be administered with a drenching gun. Appropriate drenching
equipment should be used to allow accurate dosing. This is particularly important when
administering small volumes.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Target species: Lambs and calves
Undetermined frequency
(cannot be estimated from the
available data)
Diarrhoea
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Lethargy
Gastrointestinal disorders (such as blood in faeces)
Neurological disorders (agitation, recumbency,
paresis)
Some treated animals may show signs of clinical disease even though oocyst excretion
is reduced to a very low level.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details..
Calves: in certain cases, only a transient reduction of oocyst shedding may be achieved.
Unnecessary use of antiparasitics or use deviating from the instructions given in the SPC
may increase the resistance selection pressure and lead to reduced efficacy. The decision
to use the product should be based on confirmation of the parasitic species and burden,
or of the risk of infection based on its epidemiological features, for each herd or flock.
The preferred timing of treatment is directed by the known epidemiology of spp.
and if there is no recent and confirmed history of clinical coccidiosis, the presence of
coccidia in the flock or herd should be confirmed by faecal sampling prior to treatment.
Frequent and repeated use of antiprotozoals may lead to the development of resistance
in the target parasite. Suspected clinical cases of resistance to anticoccidials should be
further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). If the
results of the test(s) confirm resistance to a particular anticoccidial, therapy should be
continued with an anticoccidial belonging to another pharmacological class and having a
different mode of action.

Special precautions for safe use in the target species:
Coccidiosis is an indicator of insufficient hygiene in the flock/pen. It is recommended to
improve hygiene and to treat all lambs in the flock and all calves in a pen.
To alter the course of an established clinical coccidial infection, in individual animals
already showing signs of diarrhoea, fluid therapy is essential, and additional supportive
therapy should be considered.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Esters of parahydroxybenzoic acid may cause allergic reactions (possibly delayed).
People with known hypersensitivity to parabens should administer the veterinary
medicinal product with caution.
Wash hands after administration of the veterinary medicinal product.
Special precautions for the protection of the environment:
Not applicable.
Other precautions:
Not applicable.
None known.
Protect from frost
Sheep (Lambs), Cattle (Calves):
Meat and offal: zero days
Not authorised for use in animals producing milk for human consumption.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.